Revvity
Daniel Castellanos is a seasoned professional in regulatory affairs and clinical studies, currently serving as the Director of Regulatory Affairs (North America) & Operations at Revvity since May 2023. Prior to this role, Castellanos held the position of Director of Clinical Studies at PerkinElmer, Inc. from January 2022 to May 2023. Experience at EUROIMMUN US, a PerkinElmer Company, includes serving as Associate Director of Regulatory Affairs and Quality Management from February 2020 to January 2022, and earlier as Senior Regulatory Affairs and Quality Management from June 2015 to February 2020. Castellanos began a career in regulatory affairs at Immunostics Inc. as a Quality Control/Quality Assurance/Regulatory Specialist from February 2013 to June 2015. Castellanos holds a Bachelor of Arts in Biology/Biological Sciences from the University of Delaware, attained in 2012, and possesses expertise in ensuring compliance with regulatory standards such as FDA, ISO 13485:2003, QMS, SOPs, GMP, and gLMPs.
This person is not in any teams
This person is not in any offices
Revvity
9 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com